Christopher A. Simon's Insider Trades & SAST Disclosures
Christopher A. Simon's most recent trade in Sotera Health Co was a trade of 19,132 Common Stock, $0.01 par value per share ("Common Stock") done . Disclosure was reported to the exchange on May 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher A. Simon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sotera Health Co | Christopher A. Simon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 19,132 | 19,132 | - | 0 | Common Stock, $0.01 par value per share ("Common Stock") | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 46,342 | 46,342 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 21,405 | 335,112 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.31 per share. | 15 May 2025 | 7,089 | 313,707 (0%) | 0% | 70.3 | 498,428 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.38 per share. | 15 May 2025 | 2,391 | 320,796 (0%) | 0% | 69.4 | 165,888 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Other type of transaction at price $ 75.56 per share. | 29 Aug 2024 | 39,704 | 322,838 (0%) | 0% | 75.6 | 3,000,034 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.64 per share. | 06 Jun 2024 | 104,516 | 433,877 (0%) | 0% | 41.6 | 4,352,046 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 104,516 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.38 per share. | 06 Jun 2024 | 71,335 | 362,542 (0%) | 0% | 87.4 | 6,233,252 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2024 | 106,062 | 371,097 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.73 per share. | 28 May 2024 | 41,736 | 329,361 (0%) | 0% | 95.7 | 3,995,387 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 32,140 | 32,140 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 14,624 | 265,035 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.73 per share. | 17 May 2024 | 4,037 | 250,411 (0%) | 0% | 95.7 | 386,462 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.80 per share. | 15 May 2024 | 1,907 | 254,448 (0%) | 0% | 94.8 | 180,784 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.49 per share. | 15 May 2024 | 1,480 | 256,355 (0%) | 0% | 96.5 | 142,805 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Mar 2024 | 38,900 | 257,546 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2023 | 196,746 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.62 per share. | 29 Jun 2023 | 196,746 | 414,113 (0%) | 0% | 28.6 | 5,629,887 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.84 per share. | 29 Jun 2023 | 117,667 | 296,446 (0%) | 0% | 84.8 | 9,982,868 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.34 per share. | 18 May 2023 | 3,839 | 217,367 (0%) | 0% | 83.3 | 319,942 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 41,177 | 41,177 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 18,225 | 222,792 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.21 per share. | 15 May 2023 | 1,586 | 221,206 (0%) | 0% | 89.2 | 141,487 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.16 per share. | 12 May 2023 | 854 | 204,567 (0%) | 0% | 88.2 | 75,289 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2022 | 8,600 | 205,124 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 62.60 per share. | 13 Jun 2022 | 1,148 | 213,724 (0%) | 0% | 62.6 | 71,865 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 59.10 per share. | 19 May 2022 | 2,496 | 214,872 (0%) | 0% | 59.1 | 147,514 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 60,891 | 60,891 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 26,041 | 217,368 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 16 May 2022 | 832 | 191,327 (0%) | 0% | 56.1 | 46,675 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 59.87 per share. | 14 Jun 2021 | 1,200 | 191,806 (0%) | 0% | 59.9 | 71,844 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.09 per share. | 07 Jun 2021 | 2,715 | 193,006 (0%) | 0% | 55.1 | 149,569 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 71,733 | 71,733 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 26,515 | 196,745 (0%) | 0% | - | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.19 per share. | 18 May 2021 | 1,024 | 195,721 (0%) | 0% | 55.2 | 56,515 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.97 per share. | 17 May 2021 | 956 | 170,230 (0%) | 0% | 56.0 | 53,507 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Dec 2020 | 194,369 | 170,941 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 87.79 per share. | 30 Jun 2020 | 5,084 | 365,310 (0%) | 0% | 87.8 | 446,324 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2020 | 102,064 | 417,411 (0%) | 0% | 0 | Common Stock | |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 87.71 per share. | 12 Jun 2020 | 45,723 | 370,394 (0%) | 0% | 87.7 | 4,010,364 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 89.29 per share. | 12 Jun 2020 | 1,294 | 416,117 (0%) | 0% | 89.3 | 115,541 | Common Stock |
| Haemonetics Corp. | Christopher A. Simon | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 97.03 per share. | 08 Jun 2020 | 2,920 | 315,347 (0%) | 0% | 97.0 | 283,328 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges